$0.06
12.83% yesterday
Nasdaq, Aug 01, 05:41 pm CET
ISIN
NL0014040206
Symbol
CNTGF

Centogene NV Stock price

$0.06
-0.09 58.65% 1M
-0.08 54.79% 6M
-0.07 53.32% YTD
-0.27 81.10% 1Y
-1.34 95.48% 3Y
-12.71 99.50% 5Y
-12.43 99.49% 10Y
-12.43 99.49% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
+0.01 12.83%
ISIN
NL0014040206
Symbol
CNTGF

Key metrics

Basic
Market capitalization
$1.6m
Enterprise Value
$71.6m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.0 | 0.0
EV/Sales
0.9 | 1.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-32.8%
Return on Equity
140.5%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $70.0m
EBITDA
- | -
EBIT
- | $-46.6m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 26.3%
EBITDA
- | -
EBIT
- | -45.5%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
0.7%
Employees
-
Rev per Employee
-
Show more

Is Centogene NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Centogene NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Centogene NV forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Centogene NV forecast:

Buy
89%
Hold
11%

Financial data from Centogene NV

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
84 84
6% 6%
100%
- Direct Costs 53 53
13% 13%
63%
31 31
4% 4%
37%
- Selling and Administrative Expenses 79 79
8% 8%
94%
- Research and Development Expense 22 22
28% 28%
26%
-47 -47
14% 14%
-56%
- Depreciation and Amortization 8.69 8.69
27% 27%
10%
EBIT (Operating Income) EBIT -56 -56
16% 16%
-67%
Net Profit -68 -68
23% 23%
-82%

In millions USD.

Don't miss a Thing! We will send you all news about Centogene NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Head office Netherlands
CEO David Jiménez
Founded 2018
Website www.centogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today